Literature DB >> 34642390

Development and validation of a neural network for NAFLD diagnosis.

Paolo Sorino1, Angelo Campanella1, Caterina Bonfiglio1, Antonella Mirizzi1, Isabella Franco1, Antonella Bianco1, Maria Gabriella Caruso2, Giovanni Misciagna3, Laura R Aballay4, Claudia Buongiorno1, Rosalba Liuzzi1, Anna Maria Cisternino5, Maria Notarnicola2, Marisa Chiloiro6, Francesca Fallucchi7, Giovanni Pascoschi8, Alberto Rubén Osella9.   

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) affects about 20-30% of the adult population in developed countries and is an increasingly important cause of hepatocellular carcinoma. Liver ultrasound (US) is widely used as a noninvasive method to diagnose NAFLD. However, the intensive use of US is not cost-effective and increases the burden on the healthcare system. Electronic medical records facilitate large-scale epidemiological studies and, existing NAFLD scores often require clinical and anthropometric parameters that may not be captured in those databases. Our goal was to develop and validate a simple Neural Network (NN)-based web app that could be used to predict NAFLD particularly its absence. The study included 2970 subjects; training and testing of the neural network using a train-test-split approach was done on 2869 of them. From another population consisting of 2301 subjects, a further 100 subjects were randomly extracted to test the web app. A search was made to find the best parameters for the NN and then this NN was exported for incorporation into a local web app. The percentage of accuracy, area under the ROC curve, confusion matrix, Positive (PPV) and Negative Predicted Value (NPV) values, precision, recall and f1-score were verified. After that, Explainability (XAI) was analyzed to understand the diagnostic reasoning of the NN. Finally, in the local web app, the specificity and sensitivity values were checked. The NN achieved a percentage of accuracy during testing of 77.0%, with an area under the ROC curve value of 0.82. Thus, in the web app the NN evidenced to achieve good results, with a specificity of 1.00 and sensitivity of 0.73. The described approach can be used to support NAFLD diagnosis, reducing healthcare costs. The NN-based web app is easy to apply and the required parameters are easily found in healthcare databases.
© 2021. The Author(s).

Entities:  

Mesh:

Year:  2021        PMID: 34642390      PMCID: PMC8511336          DOI: 10.1038/s41598-021-99400-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  52 in total

1.  Analysing and improving the diagnosis of ischaemic heart disease with machine learning.

Authors:  M Kukar; I Kononenko; C Groselj; K Kralj; J Fettich
Journal:  Artif Intell Med       Date:  1999-05       Impact factor: 5.326

2.  Machine Learning Methods to Predict Diabetes Complications.

Authors:  Arianna Dagliati; Simone Marini; Lucia Sacchi; Giulia Cogni; Marsida Teliti; Valentina Tibollo; Pasquale De Cata; Luca Chiovato; Riccardo Bellazzi
Journal:  J Diabetes Sci Technol       Date:  2017-05-12

3.  Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population.

Authors:  T C-F Yip; A J Ma; V W-S Wong; Y-K Tse; H L-Y Chan; P-C Yuen; G L-H Wong
Journal:  Aliment Pharmacol Ther       Date:  2017-06-06       Impact factor: 8.171

4.  Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD.

Authors:  Gong Feng; Kenneth I Zheng; Yang-Yang Li; Rafael S Rios; Pei-Wu Zhu; Xiao-Yan Pan; Gang Li; Hong-Lei Ma; Liang-Jie Tang; Christopher D Byrne; Targher Giovanni; Na He; Man Mi; Yong-Ping Chen; Ming-Hua Zheng
Journal:  J Hepatobiliary Pancreat Sci       Date:  2021-04-28       Impact factor: 7.027

5.  Machine learning approach to predict protein phosphorylation sites by incorporating evolutionary information.

Authors:  Ashis Kumer Biswas; Nasimul Noman; Abdur Rahman Sikder
Journal:  BMC Bioinformatics       Date:  2010-05-21       Impact factor: 3.169

6.  A simple index of lipid overaccumulation is a good marker of liver steatosis.

Authors:  Giorgio Bedogni; Henry S Kahn; Stefano Bellentani; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2010-08-25       Impact factor: 3.067

7.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

Review 8.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

Review 9.  Ultrasound-based techniques for the diagnosis of liver steatosis.

Authors:  Giovanna Ferraioli; Livia Beatriz Soares Monteiro
Journal:  World J Gastroenterol       Date:  2019-10-28       Impact factor: 5.742

10.  Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet.

Authors:  Douglas Mahana; Chad M Trent; Zachary D Kurtz; Nicholas A Bokulich; Thomas Battaglia; Jennifer Chung; Christian L Müller; Huilin Li; Richard A Bonneau; Martin J Blaser
Journal:  Genome Med       Date:  2016-04-27       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.